On July 2017 PeptiDream Inc., a public Tokyo-based biopharmaceutical company, PeptiDream and Kleo Pharmaceuticals Inc., a New Haven-based company using its proprietary Antibody Recruiting Molecule ("ARM") and Synthetic Antibody Mimic ("SyAM") platform technologies to develop small molecule immunotherapies ("Kleo"), reported a collaboration agreement to co-develop proprietary immune-oncology products in multiple indications (Press release, PeptiDream, JUL 18, 2017, View Source [SID1234537204]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System ("PDPS") technology to identify macrocyclic/constrained peptides against multiple oncology targets of interest selected by Kleo, and to optimize hit peptides into optimized binders that will be engineered by Kleo into novel ARM and SyAM products. Kleo will receive an upfront payment and will have the right to develop and commercialize all compounds resulting from the collaboration. PeptiDream is eligible to receive a tiered share of proceeds from any products that arise from the collaboration based on degree to which PeptiDream funds development of the product. Specific financial terms were not disclosed.
"We are very excited to enter into this collaboration agreement with PeptiDream ," said Douglas Manion, MD, CEO of Kleo. "We think combining PeptiDream’s PDPS technology with Kleo’s ARM and SyAM platform represents a truly potent partnership that will generate many more effective targeted treatments for patients. We are looking forward to advancing this new paradigm of small molecule immunotherapies into the clinic."
"PeptiDream has long been on the forefront of transforming PDPS-identified peptides into peptide therapeutics, small molecule drugs, and peptide drug conjugates (PDCs)," said Keiichi Kubota, CEO of PeptiDream. "We greatly look forward to working with innovative leaders like Kleo to leverage our capabilities to develop the next generation of first-in-class and best-in-class immunotherapies."